Canaccord analyst Edward Nash raised the firm’s price target on Corcept Therapeutics (CORT) to $110 from $100 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Wins FDA Approval for Lifyorli Ovarian Cancer Therapy
- Corcept confirms FDA approves Lifyorli for platinum-resistant ovarian cancer
- Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?
- Corcept Therapeutics: Early Lifyorli Approval and Robust Long‑Term Sales Outlook Underpin Buy Rating and $60 Target
- Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright